Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778880 | 1.00 | MEN1 (0.66) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL17272 | 1.00 | MEN1 (0.66) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL18022826 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL12391433 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL31510126 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970461 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL5496481 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4588381 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Potassium SCHEMBL31108362 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Bromide SCHEMBL28246248 | 0.98 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653295-B2 | Protease inhibitor; viricide | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | claimed |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-04-03 | — | — | US | claimed |
| WO-2002048116-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | claimed |
| US-20170014468-A1 | METHODS OF USE FOR THERAPEUTICS TARGETING THE PATHOGEN PORPHYROMONAS GINGIVALIS | Cortexyme, Inc. | 2017-01-19 | — | — | US | disclosed |
| EP-1333024-B1 | PEPTIDE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESSES FOR PREPARATION OF BOTH, AND USE THEREOF | UNIV KYUSHU NAT UNIV CORP (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-6951843-B2 | Peptide derivatives and their pharmaceutically acceptable salts, thereof, processes for preparation of both and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6653295-B2 | Protease inhibitor; viricide | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-1333024-A1 | PEPTIDE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESSES FOR PREPARATION OF BOTH, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030087828-A1 | Peptide derivatives and pharmaceutically acceptable salts, thereof, processes for preparation of both, and use thereof | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2003-05-08 | — | — | US | disclosed |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-04-03 | — | — | US | disclosed |
| WO-2002048116-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| EP-0228661-B1 | ISOXAZOLO-PYRIDO-BENZOXAZINE AND ISOTHIAZOLO-PYRIDO-BENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| EP-0386611-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-09-12 | — | — | EP | disclosed |
| US-4687770-A | Isoxazolo-pyrido-benzoxazine and isothiazolo-pyrido-benzoxazine derivatives | ABBOTT LABORATORIES (US) | 1987-08-18 | — | — | US | disclosed |
| EP-0228661-A1 | Isoxazolo-pyrido-benzoxazine and isothiazolo-pyrido-benzoxazine derivatives | ABBOTT LABORATORIES (US) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | PRSS1, SERPINB1, SPINT2 | MEN1 3568/4885KMT2A 3760/4885NPSR1 3667/4885 |
| US-20030087828-A1 | Peptide derivatives and pharmaceutically acceptable salts, thereof, processes for preparation of both, and use thereof | NGLY1, DOHH, VIP | MEN1 935/4885KMT2A 3970/4885NPSR1 172/4885 |
| US-20170014468-A1 | METHODS OF USE FOR THERAPEUTICS TARGETING THE PATHOGEN PORPHYROMONAS GINGIVALIS | AGER, CD38, APP | MEN1 2673/4885KMT2A 2520/4885NPSR1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.